BFRG (Bullfrog AI Holdings Inc.) stock: $0.52, $9.6M market cap, $6.9M cash, $2.8M EV, $14.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
BullFrog AI Holdings is an AI-driven drug development company that uses AI and machine learning, including its bfLEAP platform, to advance medicines for internal and external projects. It aims to increase the probability of success and decrease the time and cost involved in developing therapeutics.
Partnerships George Washington University: exclusive worldwide license (Jan 2022); $20K initiation fee, 3% royalty + sublicense fees
Indications
Hepatocellular carcinoma(Preclinical)
Obesity / NAFLD / NASH(Preclinical)
Status note siRNA targeting Beta2-spectrin. Preclinical; company has not yet initiated development activities or IND-enabling studies (all R&D to date by licensor). BullFrog AI's core business is its bfLEAP AI/ML drug-development platform (fee-for-service); this is one of three in-licensed internal drug assets.
Status note Improved formulation of mebendazole evaluated in an investigator Phase 1 trial (NCT01729260) in newly diagnosed glioma with adjuvant temozolomide. Company is seeking a partner to conduct additional clinical trials.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.